At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

Dr Joshi: Vigilance is the key. The drugs must be taken under strict supervision. Common side effects like nausea, vomitting, ...